As discussed at the end of January, Myriad has given up its Quixotic quest to validate its BRCA gene testing franchise and has abandoned its several lawsuits (many of which were consolidated before the District of Utah under 28 U.S.C. § 1407 and captioned In Re: BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation ; see " Panel on Multidistrict Litigation Consolidates Myriad Cases in Utah District Court "). With its agreement to dismiss actions (with prejudice) against Ambry Genetics, LabCorp, Invitae, and Pathway Genomics, the earlier settlement agreement reached with Gene-by-Gene ( see " Gene-by-Gene Cries Uncle, Settles with Myriad Genetics "), and a separate settlement with Counsyl, the only actions remaining before the Utah court were against Quest and GenDx. Until this week, when Quest and Myriad announced that this case has settled as well.